Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Figure: Money Raised in 2015

    Liking Japan's retail exodus Money Raised in 2015 Last week, the biotech industry raised $2,243 million, bringing to $40.5 billion the total raised year-to-date. In 2014, a total of $54.6 billion was raised, …

    Published on 4/20/2015
  • Table: Earnings on deck

    Liking Japan's retail exodus Earnings on deck At least 14 biotechs are expected to report earnings this week. Company Date Pre/post mkt 1Q15 EPS est 1Q14 EPS Expected chg Actelion Ltd. (SIX:ATLN) 4/21 …

    Published on 4/20/2015
  • X marks the spot for Atlas

    Now life sciences-only, what VC Atlas plans to do with $280M Fund X

    Finance X marks the spot for Atlas With last week's close of its oversubscribed $280 million tenth fund, Atlas Venture completed its transition into a solely life sciences-focused venture firm looking at early …

    Published on 4/20/2015
  • Liking Japan's retail exodus

    Why a specialist investor thinks retail exodus is good for Japanese biotech

    Finance Ebb & Flow Liking Japan's retail exodus Table: Earnings on deck Figure: Money Raised in 2015 At least one Japanese specialist investor hopes the ongoing rotation out of biotech by the country's retail …

    Published on 4/20/2015
  • Biocartis looks to go big on Euronext

    Why Biocartis is aiming for big Euronext IPO rather than floating in U.S.

    Finance Biocartis looks to go big on Euronext Biocartis Group N.V.'s proposed flotation on Euronext would be the largest European IPO so far this year and the largest biotech IPO on Euronext since Ipsen Group (…

    Published on 4/20/2015
  • Prenatal and beyond

    Why Sofinnova led $55.5M F round for molecular diagnostics play Natera

    Finance Prenatal and beyond Natera Inc. is keeping mum on its financing plans, but the commercial-stage molecular diagnostics company is the latest in a string of life sciences companies raising venture rounds …

    Published on 4/20/2015
  • Cash for new class

    120M B round allows antibiotic play Nabriva to dictate timing of IPO

    Ebb & Flow Ebb & Flow Cash for new class Figure: Money Raised in 2015 With antibiotics back in focus for investors, Nabriva Therapeutics AG attracted a handful of U.S. crossover investors for a $120 million …

    Published on 4/13/2015
  • Figure: Money Raised in 2015

    Cash for new class Money Raised in 2015 Last week, the biotech industry raised $793 million, bringing to $38.1 billion the total raised year-to-date. In 2014, a total of $54.6 billion was raised, including $21.5 …

    Published on 4/13/2015
  • The Woodford effect

    How strong demand for Woodford fund could be shot in arm for U.K. biotech

    Ebb & Flow The Woodford effect Woodford Investment Management LLP's latest fund should bring a fresh injection of capital into the U.K.'s life sciences sector, as strong demand prompted the firm to boost the maximum…

    Published on 4/13/2015
  • OrbiMed turns True North

    What True North plans to do with $35M B round led by OrbiMed

    Ebb & Flow OrbiMed turns True North An untranched $35 million series B round will give True North Therapeutics Inc. runway to move its lead program targeting the complement pathway into the clinic this quarter and a…

    Published on 4/13/2015
  • Figure: Money Raised in 2015

    Cashing in on Kadcyla Money Raised in 2015 Last week, the biotech industry raised $1,685 million, bringing to $37 billion the total raised year-to-date. In 2014, a total of $54.6 billion was raised, including $21.…

    Published on 4/6/2015
  • Figure: Biotech fund flows

    Fundamental rally Biotech fund flows About $3.8 billion flowed into biotech funds last quarter, compared with $4.3 billion of net inflows in 1Q14. The BioCentury 100 gained 19% in 1Q15. The March fund flows figure…

    Published on 4/6/2015
  • Table: Follow-on performance

    Fundamental rally Follow-on performance Ninety-two biotechs raised $11.3 billion in 94 follow-ons in 1Q15, matching the total raised in the full year 2014. Excluding the $1.5 billion raised by Valeant …

    Published on 4/6/2015
  • Table: IPO performance

    Fundamental rally IPO performance Biotech companies raised $2 billion in 22 IPOs in 1Q15. The total is less than the $2.6 billion raised by 36 companies in 1Q14, but has only slowed slightly from 4Q14, when 24 …

    Published on 4/6/2015
  • Table: IPO queue

    Fundamental rally IPO queue At least 18 companies have announced plans to go public since the start of 1Q15, bringing the IPO queue to at least 32. Unless noted, companies are seeking to list on NASDAQ. Most …

    Published on 4/6/2015
  • Flagship ramps up

    How Flagship plans to invest new $537M fund in healthcare

    Finance Flagship ramps up Flagship Ventures closed its fifth fund at $537 million late last month, above its $300 million target and nearly double its last fund, based on strong demand by existing LPs and a few new…

    Published on 4/6/2015
  • Vivo doubles up

    How Vivo Capital plans to invest its largest fund yet in China, U.S.

    Finance Vivo doubles up Vivo Capital believes it can put a larger amount of capital to work in the U.S. and China. So the firm closed its eighth fund late last month with $750 million -- its largest to date and …

    Published on 4/6/2015
  • Q is for quiet

    Investors look for cancer immunotherapy combination, gene therapy data in 2Q15

    With few big pending approvals, investors expect a quiet start to 2Q15 before a deluge of cancer immunotherapy combo data at ASCO.

    Published on 4/6/2015
  • Table: 2Q15 milestones

    Q is for quiet 2Q15 milestones Selected products with Phase III or regulatory milestones expected in 2Q15. (A) Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is acquiring Auspex Pharmaceuticals Inc. (NASDAQ:ASPX…

    Published on 4/6/2015
  • Figure: London vs. Europe

    Up, up and acquired

    Published on 4/6/2015
  • Figure: Price-to-earnings: BT vs. RX

    Up, up and acquired Price-to-earnings: BT vs. RX The average biotech and big pharma P/Es each increased by about 10% from 4Q14. The average biotech P/E gained 11% to 24.9 from 22.4 in 4Q14. Multiples for Biogen …

    Published on 4/6/2015
  • Figure: Results by market cap

    Up, up and acquired

    Published on 4/6/2015
  • Table: 1Q approvals

    Up, up and acquired 1Q approvals and setbacks Selected first quarter approvals. Company Approval AbbVie Inc. (NYSE:ABBV)/Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) EC approves Exviera dasabuvir and Viekirax …

    Published on 4/6/2015
  • Table: Index performance

    Up, up and acquired Index performance Index 1Q15 BioCentury 100 19% NYSE Arca Biotechnology 16% NASDAQ Biotechnology 13% BioCentury Europe 12% NYSE Arca Pharmaceutical 7% NASDAQ Composite 3% …

    Published on 4/6/2015
  • Table: Restructuring watch

    Up, up and acquired Restructuring watch At least five companies announced plans to restructure in the first quarter compared with at least two in the same period last year. All cash and operating loss figures in $…

    Published on 4/6/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993